Prevalence of the metabolic syndrome in Danish psychiatric outpatients treated with antipsychotics

References

• Alberti, KG, Zimmet P, Shaw J. The metabolic syndrome—A new worldwide definition. Lancet 2005;366:1059–62.
   PubMed Web of Science ®Google Scholar
• Executive summary of the third report of the national education program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001;285:2486–97.
   PubMed Web of Science ®Google Scholar
• McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L . Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophrenia Research 2005;80:19–32.
   PubMed Web of Science ®Google Scholar
• Holt R, Abdelrahman T, Hirsch M, Dhesi Z, George T, Blincoe T, . The prevalence of undiagnosed metabolic abnormalities in people with serious mental illness. J Psychopharmacol 2010;24:867–73.
   PubMed Web of Science ®Google Scholar
• De Hert M, Dekker JM, Wood D, Kahl KG, Holt RIG, Möller HJ. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). European Psychiatry 2009;24:412–24.
   PubMed Web of Science ®Google Scholar
• Van Os J, Kapur S. Schizophrenia. Lancet 2009;374:635–45.
   PubMed Web of Science ®Google Scholar
• Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia. Arch Gen Psychiatry 2007;64:1123–31.
   PubMed Web of Science ®Google Scholar
• Tiihonen J, Lönnqvist J, Wahlbeck K, Klaukka T, Niskanen L, Tanskanen A, . 11-year follow-up of mortality in patients with schizophrenia: A population-based cohort study (FIN11 study). Lancet 2009;374:620–27.
   PubMed Web of Science ®Google Scholar
• Saddichha S, Manjunatha N, Ameen S, Akhtar S. Metabolic syndrome in first episode schizophrenia—A randomized double-blind controlled, short-term prospective study. Schizophrenia Res 2008;101:266–72.
   PubMed Web of Science ®Google Scholar
• Stahl SM, Mignon L, Meyer JM. Which comes first: Atypical antipsychotic treatment or cardiometabolic risk? Acta Psychiatr Scand 2009;119:171–9.
   PubMed Web of Science ®Google Scholar
• Verma SK, Subramaniam M, Liew A, Poon LY. Metabolic risk factors in drug-naïve patients with first-episode psychosis. J Clin Psychiatry 2009;70:997–1000.
   PubMed Web of Science ®Google Scholar
• Arango C, Bobes J, Aranda P, Carmena R, Garcia-Garcia M, Rejas J. A comparison of schizophrenia outpatients treated with antipsychotics with and without metabolic syndrome: Findings from the CLAMORS study. Schizophr Res 2008;104:1–12.
   PubMedGoogle Scholar
• Newcomer JW. Metabolic considerations in the use of antipsychotic medications: A review of recent evidence. J Clin Psychiatry 2007;68:20–7.
   PubMed Web of Science ®Google Scholar
• Pramyothin P, Khaodhiar L. Metabolic syndrome with the atypical antipsychotics. Curr Opin Endocrinol Diabetes Obes 2010;17: 460–6.
   PubMed Web of Science ®Google Scholar
• Laursen TM, Munk-Olsen T, Nordentoft M, Mortensen PB. Increased mortality among patients admitted with major psychiatric disorders: A register-based study comparing mortality in unipolar depressive disorder, bipolar affective disorder, schizoaffective disorder and schizophrenia. J Clin Psychiatry 2007;68:899–907.
   PubMed Web of Science ®Google Scholar
• Correll CU, Frederickson AM, Kane JM, Manu P. Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second-generation antipsychotics. Bipolar Disorders 2008;10:788–97.
   PubMed Web of Science ®Google Scholar
• Suvisaari JM, Saarni SI, Perälä J, Suvisaari JV, Härkänen T, Lönnqvist J, . Metabolic syndrome among persons with schizophrenia and other psychotic disorders in a general population survey. J Clin Psychiatry 2007;68:1045–55.
   PubMed Web of Science ®Google Scholar
• John AP, Koloth R, Dragovic M, Lim SC. Prevalence of metabolic syndrome among Australians with severe mental illness. Med J Aust 2009;190:176–9.
   PubMed Web of Science ®Google Scholar
• Hagg S, Lindblom Y, Mjorndal T, Adolfsson R. High prevalence of the metabolic syndrome among a Swedish cohort of patients with schizophrenia. International Clin Psychopharmacology 2006;21: 93–8.
   PubMed Web of Science ®Google Scholar
• Birkenaes AB, Søgaard AJ, Engh JA, Jonsdottir H, Ringen PA, Vaskinn A, . Sociodemographic characteristics and cardiovascular risk factors in patients with severe mental disorders compared with the general population. J Clin Psychiatry 2006;67: 425–33.
   PubMed Web of Science ®Google Scholar
• Heiskanen T, Niskanen L, Lyytikainen R, Saarinen PI, Hintikka J. Metabolic syndrome in patients with schizophrenia. J Clin Psychiatry 2003;64:575–579.
   PubMed Web of Science ®Google Scholar
• Larsen JT, Fagerquist M, Holdrup M, Christensen B, Sigalin C, Nilsson PM. Metabolic syndrome and psychiatrists’ choice of follow-up interventions in patients treated with atypical antipsychotics in Denmark and Sweden. Nordic J Psych 2010; 65:40–6.
   PubMedGoogle Scholar
• Thyssen JP, Linneberg A, Menné T, Nielsen NH, Johansen JD. The prevalence and morbidity of sensitization to fragrance mix I in the general population. Br J Dermatol 2009;161:95–101.
   PubMed Web of Science ®Google Scholar
• Schorr SG, Slooff CJ, Bruggeman R, Taxis K. Prevalence of metabolic syndrome in patients with psychotic disorders in the Netherlands. J Clin Psychopharmacol 2009;29:399–402.
   PubMedGoogle Scholar
• De Hert MA, van Winkel R, Van Eyck D, Hanssens L, Wampers M, Scheen A, . Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophrenia Res 2006;83:87–93.
   PubMed Web of Science ®Google Scholar
• De Hert M, Schreurs V, Sweers K, Van Eyck D, Hanssens L, Sinko S, . Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: A retrospective chart review. Schizophrenia Res 2008;101:295–303.
   PubMed Web of Science ®Google Scholar
• Meyer JM, Davis VG, Goff DC, McEvoy JP, Nasrallah HA, Davis SM, . Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE schizophrenia trial: Prospective data from phase 1. Schizophrenia Res 2008;101:273–86.
   PubMed Web of Science ®Google Scholar
• JBS 2: Joint British Societies’ guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005;91:v1–v52.
   Web of Science ®Google Scholar
• Nasrallah HA, Newcomer JW. Atypical antipsychotics and metabolic dysregulation: Evaluating the risk/benefit equation and improving the standard of care. J Clin Psychopharmacol 2004;24: S7–14.
   PubMedGoogle Scholar
• Madsbad S, Astrup AV. Obesity, the metabolic syndrome and cardiovascular disease. Ugeskrift for læger 2004;166:1561–4.
   PubMedGoogle Scholar